Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The article of Liem et al 1 addressed important issues of finite nucleos(t)ide analogues (NUC) therapy in mostly Asian (>95%) patients with chronic hepatitis B. It is a randomised controlled trial (RCT) on this issue second to that of the first but a smaller one involving mainly (85%–90%) Caucasian patients.2 Whereas recent controlled and cohort studies in pretherapy HBeAg-negative patients have provided evidence of much increased HBsAg loss rate after stopping NUC therapy,2–6 the reasons of the contradictory conclusion of this study and several critical points of this trial deserve clarification and further discussion.
First, only 42% of the 159 patients agreed to be enrolled. Are there any bias comparing …
Y-FL and W-JJ contributed equally.
Contributors Y-FL and W-JL co-wrote this letter and contributed equally.
Funding This work was supported by grants from the Chang Gung Medical Research Programme (CMRPG1G0061-3, CMRPG3A0901-3, CORPG3G0651), National Science Council, Taiwan (MOST105-2628-B-182-011-MY3) and the Prosperous Foundation, Taipei, Taiwan.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.